Posted on 12/8/20
Syros Closes $90.5 Million Strategic Financing
Syros Pharmaceuticals (NASDAQ:SYRS), a leader in the development of medicines that control the expression of genes, announced today that it has closed a previously announced private . . .
Posted on 12/8/20
Peak Physical Therapy & Sports Performance Promotes Samantha Meade to Lead Physical Therapy Aide for the Company
Physical Therapy & Sports Performance, a South Shore practice specializing in unique programs that provide comprehensive
Posted on 12/8/20
Trinity Life Sciences Acquires BluePrint Research Group
Trinity Life Sciences, the leading commercial partner to the life sciences industry, announced the acquisition of New Jersey-based BluePrint Research Group. The acquisition positions Trinity
Posted on 12/8/20
Pear Therapeutics Closes $80M Series D Financing
Pear Therapeutics, Inc., today announced that it has successfully closed an $80 million Series D financing led by SoftBank Vision Fund 21 with participation
Posted on 12/8/20
Vigil Neuroscience Launches $50 Million Series A
Vigil Neuroscience, a new biotechnology company harnessing the power of microglia for the treatment of neurodegenerative diseases, launched today with $50 million Series A financing.
Posted on 12/8/20
Bristol-Myers Squibb Contingent Value Rights: Final Inspection Is Happening
SummaryThe contingent value right issued to Celgene shareholders after the Bristol-Myers acquisitions are dependent on approval of Liso-cell and Ide-cell.For Liso-cell to be approved the FDA . . .
Posted on 12/8/20
Could Moderna Be a Millionaire-Maker Stock?
Moderna (NASDAQ:MRNA) has made some investors quite wealthy this year. Its shares have skyrocketed over 680% year to date fueled by excitement over its COVID-19 vaccine . . .
Posted on 12/8/20
Canada Doubles Its Commitment to Moderna's Coronavirus Vaccine to 40 Million Doses
In the likely case that Canadian regulators approve Moderna's (NASDAQ:MRNA) coronavirus vaccine candidate -- mRNA-1273 -- the country will receive twice as many doses as previously . . .
Posted on 12/8/20
Syndax Announces Proposed Public Offering of Common Stock
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that it plans to offer and sell, subject . . .
Posted on 12/7/20
CVS Health Corporation Cash Tender Offers for Certain Outstanding Notes
CVS Health Corporation (NYSE: CVS) announced today that it has commenced cash tender offers for (i) up to $1,500,000,000 aggregate principal amount of its 4.000% Senior . . .
Posted on 12/7/20
Repligen Corporation Proposes Public Offering of Shares of Common Stock
WALTHAM, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Repligen Corporation (NASDAQ: RGEN) today announced that it has commenced an underwritten public offering of 1.5 million shares . . .
Posted on 12/7/20
Is Moderna's Stock Price Ridiculously Expensive Right Now?
A hot stock can heat up to the point that its sizzle fizzles. Some investors are wondering if that fate is in store for Moderna (NASDAQ:MRNA).Excitement . . .
Posted on 12/6/20
Intellia Therapeutics Closes $201M Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both . . .
Posted on 12/6/20
Cogent Biosciences Closes Upsized Public Offering of Common Stock
Cogent Biosciences, Inc. (NASDAQ: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the closing of its upsized underwritten public offering . . .
Posted on 12/4/20
Foghorn Therapeutics Announces Third Quarter 2020 Financial Results and Provides Corporate Update
CAMBRIDGE, Mass., Dec. 04, 2020 (GLOBE NEWSWIRE) -- December 4, 2020—Foghorn Therapeutics Inc. (Nasdaq: FHTX), a company pioneering the discovery and development of a new class . . .
Posted on 12/4/20
Merck Just Sold Off Its Moderna Shares for a Huge Gain. Should You?
Practically everything is going right for Moderna (NASDAQ:MRNA) these days. The biotech announced surprisingly positive efficacy results for its COVID-19 vaccine candidate mRNA-1273, and it has . . .
Posted on 12/4/20
Is Vertex Pharmaceuticals Stock a Buy?
Vertex Pharmaceuticals (NASDAQ:VRTX) is rapidly revolutionizing the treatment of cystic fibrosis, a devastating genetic condition that inhibits the lungs' ability to breathe and causes infections. More . . .
Posted on 12/4/20
Could Moderna Be a Millionaire-Maker Stock?
2020 has nearly come to an end, and the world is still engulfed in the deadly coronavirus pandemic. Globally, cases have crossed the 64 million mark, . . .
Posted on 12/4/20
Should Investors Buy Moderna Stock for Its Coronavirus Vaccine?
On the surface, Moderna (NASDAQ:MRNA) looks like a great growth stock backed by its coronavirus vaccine. And the biotech also has potential to use its messenger . . .
Posted on 12/4/20
Sigilon Therapeutics Prices Upsized Initial Public Offering
CAMBRIDGE, Mass., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Sigilon Therapeutics, Inc., a biotechnology company that seeks to develop functional cures for chronic diseases through its Shielded . . .
Posted on 12/3/20
Lantheus Holdings Sell Its Puerto Rico Radiopharmacy and PET Manufacturing Facility
NORTH BILLERICA, Mass.--(BUSINESS WIRE)--Lantheus Holdings, Inc. (NASDAQ: LNTH) (the Company), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader . . .
Posted on 12/2/20
BeiGene Prices of Public Offering
CAMBRIDGE, Mass. & BEIJING--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160), a commercial-stage biotechnology company focused on developing and commercializing innovative medicines worldwide, today announced the pricing . . .
Posted on 12/2/20
Infinity Pharmaceutical Reaching Vital New Staging Posts
SummaryRecent results pleased analysts.The company's relationship with various Big Pharma companies will be key to future revenues and to the stock price.The market in general sees . . .
Posted on 12/2/20
IPO Update: Sigilon Therapeutics Aims For $101 Million IPO
SummarySigilon Therapeutics has filed proposed terms for its $101 million U.S. IPO.The firm is advancing programs to treat blood, lysosomal storage and other diseases.SGTX has produced . . .
Posted on 12/2/20
Intellia Therapeutics Prices of Public Offering of Common Stock
CAMBRIDGE, Mass., Dec. 01, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both . . .
Boston
